Viyash Scientific Limited’s Board of Directors met on August 11, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board also approved the allotment of 10,30,775 equity shares under the ESOP Scheme 2026, increasing the paid-up capital. Additionally, an investment of up to Rs. 400.02 crore in its wholly-owned subsidiary, Alivira Animal Health Limited, via a Rights Issue was sanctioned to strengthen its capital structure.
Viyash Scientific Board Meeting Highlights
The Board of Directors of Viyash Scientific Limited convened on Tuesday, August 11, 2026, to consider and approve key corporate actions. The primary outcomes of the meeting included the approval of the company’s unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the independent auditor’s limited review report.
Employee Stock Option Allotment
In a significant move, the Board approved the allotment of 10,30,775 equity shares of Rs. 2/- each, fully paid, to eligible optionees under the Viyash Scientific Limited Employee Stock Option Scheme, 2026 (‘ESOP Scheme 2026’). These shares were issued at an exercise price of Rs. 101/- per equity share. This allotment will result in an increase of the company’s issued and paid-up equity share capital, bringing the total number of equity shares to 43,99,07,588.
Strategic Subsidiary Investment
Furthermore, the Board approved the subscription to equity shares of Alivira Animal Health Limited (‘AAHL’), a wholly-owned subsidiary, through a Rights Issue. The overall consideration for this investment is up to Rs. 400,02,15,648 (Rupees Four Hundred Crore Two Lakh Fifteen Thousand Six Hundred and Forty-Eight Only). This strategic investment is intended to strengthen AAHL’s capital structure and reduce its interest burden. The company also approved the incorporation of a step-down subsidiary in Vietnam.
Financial Performance Overview (Unaudited Standalone – Q1 FY27)
Revenue and Profitability
For the quarter ended June 30, 2026, Viyash Scientific reported total income of Rs. 3,724.90 million. Total expenses stood at Rs. 3,403.90 million, leading to a profit before tax and exceptional items of Rs. 321.00 million (Profit before tax V-VI: Rs. 278.90 million). The profit after tax for the quarter was Rs. 209.20 million. Total comprehensive income, net of tax, was Rs. 206.50 million.
Earnings Per Share
Basic Earnings Per Equity Share for the quarter was Rs. 0.48, while Diluted Earnings Per Equity Share was Rs. 0.47.
Consolidated Financial Performance (Unaudited – Q1 FY27)
Revenue and Profitability
On a consolidated basis for the quarter ended June 30, 2026, the Group reported total income of Rs. 9,546.70 million. Total expenses amounted to Rs. 8,422.60 million. Profit before tax and exceptional items was Rs. 1,124.10 million, and profit after tax was Rs. 792.90 million. Total comprehensive income, net of tax, stood at Rs. 729.50 million.
Earnings Per Share
Basic Earnings Per Equity Share on a consolidated basis was Rs. 1.51, and Diluted Earnings Per Equity Share was Rs. 1.47.
Source: BSE
